ImClone Systems, Inc.
http://www.imclone.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ImClone Systems, Inc.
Chi-Med's Surufatinib, Generic Ibrance Among Latest China Approvals
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.
BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal
BeiGene has teamed up with Novartis to take its PD-1 antibody global after an earlier major deal with Celgene was terminated following the BMS acquisition, and amid intense market and pricing competition in the immuno-oncology sector in China.
Multinationals Start 2021 Empty Handed In China National Reimbursement Race
China's latest round of reimbursement decisions show multinationals including AstraZeneca, BMS and Roche won’t be receiving national coverage for their latest immuno-oncology drugs any time soon.
Hologic Continues Spending Spree With $230M Tuck-In Acquisition Of Biotheranostics
Hologic’s recent buy-outs put it in a strengthened growth and competitive position beyond COVID.